Questions & Answers

In 2026, the traditional relationship between sponsors and Contract Research Organizations (CROs) has been completely redefined.

• End-to-End Governance: Sponsors now prefer "Full-Service Outsourcing" (FSO) models that handle everything from discovery to commercialization, rather than piecemeal task delegation.

• Risk-Sharing Agreements: Performance-based incentives are now standard. CROs are increasingly taking on financial risks alongside biotech startups, with payments tied directly to successful Phase II/III readouts.

• Agile Integration: Small-to-midsize biotechs (SMEs) are prioritizing "Niche CROs" that offer the agility and personalized technical depth that global "mega-platforms" often lack.